ALLIANCE-TO-END-PLASTIC
7.5.2020 13:02:08 CEST | Business Wire | Press release
The Alliance to End Plastic Waste (the Alliance) today announced a partnership with the ASASE Foundation to support women entrepreneurs working to reduce plastic litter in the community. The initiative called Closing the Loop uses a circular economy model to enable local communities to benefit from discarded plastic waste by collecting, reprocessing and reselling it.
Closing the Loop kicks off the Alliance’s support for projects based in Africa. It was first launched by ASASE in 2018 to provide seed money to equip a plastic waste reprocessing plant and offer technical and business management training to women entrepreneurs to run the recycling plant for profit. In the first twelve months, the project created eight jobs within the community and diverted 35 (metric) tons of plastic from waste. By partnering with the Alliance, the capacity of the reprocessing plant will increase to divert 2,000 (metric) tons of plastic waste per year and create even more jobs.
“A key pillar of ending plastic waste in the environment is the sustainable impact it will bring to the well-being of local communities. Our partnership with ASASE is especially meaningful because Closing the Loop is the right step towards a circular economy model. It directly benefits those living in areas which don’t have access to plastic waste collection and sorting systems. This initiative is a simple but scalable action, supporting the inspiring women of Ghana who are building communities towards a path to end plastic waste in the environment,” said Jacob Duer, President and CEO, Alliance to End Plastic Waste.
“What we value most in our partnership with the Alliance to End Plastic Waste is the access to the expertise in waste management, which we can leverage now in our project, effectively multiplying the impact of the funding provided by the Alliance to our project,” comments Dana Mosora, ASASE Foundation Founder and Managing Director.
The partnership has also opened the possibility to bring in expertise from academic partner, the Swiss Federal Institute of Technology, in areas of developing new end market applications and concepting a new financing system for the management of plastic waste in Ghana.
The recycling plant processes a range of plastic waste from water sachets (LDPE) to shampoo and detergent bottles (HDPE) and large cooking oil containers (HDPE), converting it into regrinds. The regrinds are then sold to recyclers to make items such as pavement blocks, sheets for construction and basins and liners, most of which goes back into the community.
About:
The Alliance to End Plastic Waste is a not-for-profit organization bringing together industry, government, communities, and civil society in the fight to end plastic waste.
ASASE Foundation enables Ghanaian women entrepreneurs to play a key role in cashing-in on the plastic waste trash of Accra for the benefit of their own communities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200507005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom